Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
99.25%
Operating Margin
92.42%
Net Margin
69.59%
Efficiency Metrics
Revenue per Expense Ratio
13.13
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
92.50%
Income Tax Rate
-0.24%
EPS
2.4800000000
Balance Sheet Analysis
Current Ratio
28.22
Cash Ratio
0.79
Working Capital
$18.10B
Debt to Equity
0.70
Debt to Assets
40.01%
Equity Ratio
57.32%
Cash Flow Analysis
Operating Cash Flow Ratio
60.38%
Free Cash Flow Ratio
60.27%
CapEx to Revenue
0.11%
Dividends Paid
$1.58B
Stock Buybacks
$4.97M
Total Shareholder Returns
$1.59B
Cash Position Change
150.12%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 12.37%
Detailed Growth Metrics
Core Performance
Revenue
38.89%
Net Income
124.90%
EPS
95.28%
Operating Income
96.16%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
23.30%
Operating Cash Flow
12.23%
Free Cash Flow
12.13%
Balance Sheet Health
Assets
17.26%
Debt
28.30%
Book Value per Share
-0.44%
Inventory
100.00%
Shareholder Returns
Dividends per Share
12.37%
Shares Outstanding
15.61%
Long Term Trends
3Y Revenue/Share
47.03%
5Y Revenue/Share
45.60%
3Y Dividend/Share
29.07%
5Y Dividend/Share
118.25%